The exercise period for the warrants of series TO 2 was created today: Immunovia AB By Investing.com

LUND, Sweden, January 2, 2025 /PRNewswire/ — Immunovia AB (publ) (“Immunovia” or “the Company”) hereby announces that today, 2 January 2025, the exercise period for the warrants of series TO 2 in Immunovia AB (publ) (“Immunovia” or “Company”) (the “Guarantee Plan”) begins. The exercise period continues until 16 January 2025.

Summary of TO 2 series guarantees

• The structure: One (1) series of warrants TO 2 entitles the holder to subscribe for one (1) new share in the Company.
• Time to exercise: 2 January 2025 – 16 January 2025.
• Subscription price: SEK 0.46 per share.
• Release volume: 124,423,978 warrants of series TO 2. After full exercise, 124,423,978 shares will be issued and the Company will receive approx. SEK 57.2 million before expenses are incurred.
• Subscription obligations and warranties: The Company has received subscription intentions from the Company’s CEO and all board members who currently have warrants, almost entirely. SEK 0.8 millioncorresponding to approximately 1.3 percent of the Guarantee Plan. In addition to the above, the Company has received subscription commitments and assurance commitments from several foreign professional investors. Overall, the subscriber commitment reaches approx SEK 0.1 millioncorresponding to approximately 0.3 percent of the Guarantee Plan, and the guarantee obligations are equal SEK 36.3 millioncorresponding to approximately 63.4 percent of the Guarantee Plan. As such, the Warranty Plan is virtually protected SEK 37.2 millioncorresponding to approximately 65.0 percent of the warranty plan. For more information, please refer to the Company’s statement published on 27 December 2024.
• Last day of trading in warrants of series TO 2: 14 January 2025.
• Share capital and dilution: Upon full exercise of all 124,423,978 warrants series TO 2, the capital stock will increase by a maximum SEK 3,732,719.34 to SEK 8,824,063.62 with the issuance of 124,423,978 new shares, which will result in the total number of shares remaining in the Company increasing from 169,711,476 to 294,135,454. In the full use of all warrants series TO 2, the dilution reaches about 42.3 percent.
• Result and delivery of new ordinary shares: The result of the use of guarantees will be published in a press release in or near the area 20 January 2025. Registered and paid-up shares may be registered in the registrant’s securities depository as interim shares (IA) until the registration of the issue has been completed at the Swedish Companies Registration Office, whereupon the interim shares will automatically be converted into shares at the Swedish Companies Registration Office. Immunovia.

Please note that series TO 2 permissions that are not used by 16 January 2025or sold by 14 January 2025they expire in vain. In order for the warrants not to expire, an active registration of the shares or sale of the warrants is required. Please note that some nominees may close their applications early 16 January 2025.

Summary of instructions and important dates

Holders of warrants who wish to exercise these to subscribe for shares shall give notice of this latter exercise 16 January 2025. Warranties never used or previously 16 January 2025 it expires without a value. Owners who do not wish to use their warranties may sell them. Warrant trading continues up to and including 14 January 2025.

Detailed information and registration instructions

Use of nominee registered warrants

Holders of warrants with their own registered securities (participating in securities custody services, investment savings accounts (ISK) or endowment insurances) must notify the use of warrants by contacting the nominees and follow the nominee’s instructions regarding registration and payment. This should happen well before 16 January 2025 as different nominees have different processing times.

Use of directly registered warrants

Warrant holders who have their assets directly registered (participating in the VP account) must notify the exercise of the warrants by filling and sending the application form to do so, so that the application form is received by the issuing agent, Share price of Vator Securities ABbefore it’s too late 16 January 2025.

An application form is available at the Company’s address and Share price of Vator Securities AB respective websites (www.immunovia.com and www.vatorsecurities.se). Please note that payment for new shares must be received by Vator Securities before it’s too late 16 January 2025 by following the instructions on the application form.

Complete warranty terms and conditions

Complete terms and conditions of warranties are available on the Company’s website, www.immunovia.com.

Counselors

Share price of Vator Securities AB works as a financial advisor and Setterwalls as a legal advisor to Immunovia regarding the use of the Guarantee Program. Share price of Vator Securities AB acts as a releasing agent.

For more information, please contact

Jeff BorcherdingCEO
jeff.borcherding@immunovia.com

Karin Almqvist Liwendahl, CFO
karin.almqvist.liyandahl@immunovia.com
+46 70 911 56 08

The information was submitted for publication, through the agency of the above-mentioned contact persons, at 8.30 CET 2 January 2025.

Immunovia in short

Immunovia AB is a diagnostic company whose mission is to increase survival rates for pancreatic cancer patients through early detection. Immunovia focuses on developing and commercializing a simple blood-based test to detect proteins and antibodies that indicate a high-risk individual has had pancreatic cancer. Immunovia collaborates and consults with health care providers, leading experts and patient advocacy groups to make its test available to people at high risk of pancreatic cancer.

USA it is the world’s largest market for pancreatic cancer detection. The company estimates that at USA1.8 million people are at high risk of breast cancer and could benefit from annual screening tests. Immunovia diseases shares (IMMNOV) are listed on Nasdaq Stockholm.

For more information, please visit www.immunovia.com.

IMPORTANT INFORMATION

The information in this press release does not contain or constitute an offer to acquire, subscribe for or trade in shares, warrants or other securities in Immunovia. Invitation to interested parties to subscribe for units with shares and warrants Immunovia made only through a prospectus published by Immunovia to 12 August 2024. The prospectus was accepted and registered by the The Swedish Financial Supervisory Authority and published on the Company’s website, www.immunovia.com.

Since Immunovia perform essential services according to the Swedish Screening of Foreign Direct Investments Act, the use of share registration guarantees may need to be reviewed by the Inspectorate of Strategic Products. The Company, no later than the time regarding the commencement of the warranty period, will publish additional information in this regard on the Company’s website, namely, www.immunovia.com.

This information is brought to you by Cision

The following files are available for download: